PMID- 23994420
OWN - NLM
STAT- MEDLINE
DCOM- 20140212
LR  - 20220317
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 62
IP  - 24
DP  - 2013 Dec 17
TI  - Allopurinol reduces left ventricular mass in patients with type 2 diabetes and 
      left ventricular hypertrophy.
PG  - 2284-93
LID - S0735-1097(13)03888-6 [pii]
LID - 10.1016/j.jacc.2013.07.074 [doi]
AB  - OBJECTIVES: This study sought to ascertain whether high-dose allopurinol causes 
      regression of left ventricular mass (LVM) in patients with type 2 diabetes 
      mellitus (T2DM). BACKGROUND: Left ventricular hypertrophy (LVH) is common in T2DM 
      and contributes to patients' high cardiovascular (CV) event rate. Oxidative 
      stress (OS) has been implicated in LVH development, and allopurinol has been 
      previously shown to reduce vascular OS. We therefore investigated whether 
      allopurinol causes regression of LVH in patients with T2DM. METHODS: We conducted 
      a randomized, double-blind, placebo-controlled study of 66 optimally-treated T2DM 
      patients with echocardiographic evidence of LVH. Allopurinol, 600 mg/day, or 
      placebo was given over the study period of 9 months. The primary outcome was 
      reduction in LVM as calculated by cardiac magnetic resonance imaging at baseline 
      and at 9 months' follow-up. Secondary endpoints were change in flow-mediated 
      dilation and augmentation index. RESULTS: Allopurinol significantly reduced 
      absolute LVM (-2.65 +/- 5.91 g vs. placebo group +1.21 +/- 5.10 g [p = 0.012]) and 
      LVM indexed to body surface area (-1.32 +/- 2.84 g/m(2) vs. placebo group +0.65 +/- 
      3.07 g/m(2) [p = 0.017]). No significant changes were seen in either 
      flow-mediated dilation or augmentation index. CONCLUSIONS: Allopurinol causes 
      regression of LVM in patients with T2DM and LVH. Regression of LVH has been shown 
      previously to improve CV mortality and morbidity. Therefore, allopurinol therapy 
      may become useful to reduce CV events in T2DM patients with LVH. (Allopurinol in 
      Patients with Diabetes and LVH; UKCRN 8766).
CI  - Copyright (c) 2013 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Szwejkowski, Benjamin R
AU  - Szwejkowski BR
AD  - Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, 
      University of Dundee, Ninewells Hospital and Medical School, Dundee, United 
      Kingdom.
FAU - Gandy, Stephen J
AU  - Gandy SJ
AD  - Department of Clinical Radiology, Ninewells Hospital and Medical School, Dundee, 
      United Kingdom.
FAU - Rekhraj, Sushma
AU  - Rekhraj S
AD  - Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, 
      University of Dundee, Ninewells Hospital and Medical School, Dundee, United 
      Kingdom.
FAU - Houston, John G
AU  - Houston JG
AD  - Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, 
      University of Dundee, Ninewells Hospital and Medical School, Dundee, United 
      Kingdom; Department of Clinical Radiology, Ninewells Hospital and Medical School, 
      Dundee, United Kingdom.
FAU - Lang, Chim C
AU  - Lang CC
AD  - Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, 
      University of Dundee, Ninewells Hospital and Medical School, Dundee, United 
      Kingdom.
FAU - Morris, Andrew D
AU  - Morris AD
AD  - Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, 
      University of Dundee, Ninewells Hospital and Medical School, Dundee, United 
      Kingdom.
FAU - George, Jacob
AU  - George J
AD  - Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, 
      University of Dundee, Ninewells Hospital and Medical School, Dundee, United 
      Kingdom. Electronic address: j.george@dundee.ac.uk.
FAU - Struthers, Allan D
AU  - Struthers AD
AD  - Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, 
      University of Dundee, Ninewells Hospital and Medical School, Dundee, United 
      Kingdom.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20130828
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 268B43MJ25 (Uric Acid)
RN  - 63CZ7GJN5I (Allopurinol)
SB  - IM
CIN - J Am Coll Cardiol. 2013 Dec 17;62(24):2294-6. PMID: 23994396
MH  - Aged
MH  - Allopurinol/*administration & dosage
MH  - Analysis of Variance
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Double-Blind Method
MH  - Female
MH  - Heart Ventricles/pathology
MH  - Humans
MH  - Hypertrophy, Left Ventricular/complications/*drug therapy
MH  - Magnetic Resonance Imaging, Cine
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Uric Acid/blood
OTO - NOTNLM
OT  - AIx
OT  - BP
OT  - CMR
OT  - CV
OT  - FMD
OT  - LV
OT  - LVH
OT  - LVMI
OT  - MRI
OT  - T2DM
OT  - allopurinol
OT  - augmentation index
OT  - blood pressure
OT  - cardiac magnetic resonance
OT  - cardiovascular
OT  - endothelial function
OT  - flow-mediated dilation
OT  - left ventricular
OT  - left ventricular hypertrophy
OT  - left ventricular mass index
OT  - magnetic resonance imaging
OT  - type 2 diabetes
OT  - type 2 diabetes mellitus
EDAT- 2013/09/03 06:00
MHDA- 2014/02/13 06:00
CRDT- 2013/09/03 06:00
PHST- 2013/03/18 00:00 [received]
PHST- 2013/07/04 00:00 [revised]
PHST- 2013/07/30 00:00 [accepted]
PHST- 2013/09/03 06:00 [entrez]
PHST- 2013/09/03 06:00 [pubmed]
PHST- 2014/02/13 06:00 [medline]
AID - S0735-1097(13)03888-6 [pii]
AID - 10.1016/j.jacc.2013.07.074 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2013 Dec 17;62(24):2284-93. doi: 10.1016/j.jacc.2013.07.074. 
      Epub 2013 Aug 28.